Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrafy Life SciencesASX:VFY -1.53%4 6-1 Month Momentum % is 117.06% as of Sep. 06, 2026. GuruFocus rates ASX:VFY with a GF Score™ of 4/100. The stock has 2 warning signs investors should review. Among 2,823 Software companies, Vitrafy Life Sciences ranks better than 97.66% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-09-06), Vitrafy Life Sciences's 6-1 Month Momentum % is 117.06%.
The industry rank for Vitrafy Life Sciences's 6-1 Month Momentum % or its related term are showing as below:
ASX:VFY's 6-1 Month Momentum % is ranked better than 97.66% of 2823
companies
in the Software industry
Industry Median: -4.95
vs ASX:VFY: 117.06
Vitrafy Life Sciences (ASX:VFY) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vitrafy Life Sciences 6-1 Month Momentum % Related Terms
ASX:VFY vs MSFT, PLTR, ORCL: 6-1 Month Momentum % Comparison
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences 6-1 Month Momentum % vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's 6-1 Month Momentum % falls into.
Vitrafy Life Sciences (ASX:VFY) 6-1 Month Momentum % Calculation
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum %
=
( Price 1-month ago
/
Price 6-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrafy Life Sciences (ASX:VFY) has a 6-1 Month Momentum % of 117.06% as of Sep. 06, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vitrafy Life Sciences and its competitors. According to the industry distribution chart, Vitrafy Life Sciences ranks #66 out of 2823 companies in the Software industry, placing it in the top 2.3%.
Is Vitrafy Life Sciences' 6-1 Month Momentum % too high?
Vitrafy Life Sciences' current 6-1 Month Momentum % is 117.06%. Based on the distribution chart, Vitrafy Life Sciences ranks #66 out of 2823 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' 6-1 Month Momentum % compare to MSFT and PLTR?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #66 out of 2823 companies for 6-1 Month Momentum %. This places Vitrafy Life Sciences in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Software company?
A good 6-1 Month Momentum % depends on the Software industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vitrafy Life Sciences and its competitors. Vitrafy Life Sciences's current 6-1 Month Momentum % is 117.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current 6-1 Month Momentum % of 117.06%. The current 6-1 Month Momentum % is 117.06%. Vitrafy Life Sciences' overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current 6-1 Month Momentum % is 117.06% as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
4GF Score
Get the complete analysis for ASX:VFY
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
